دورية أكاديمية
Molecular analysis for ovarian cancer detection in patient-friendly samples.
| العنوان: | Molecular analysis for ovarian cancer detection in patient-friendly samples. |
|---|---|
| المؤلفون: | Wever BMM; Amsterdam UMC, location Vrije Universiteit Amsterdam, Department of Pathology, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, The Netherlands., Schaafsma M; Amsterdam UMC, location Vrije Universiteit Amsterdam, Department of Pathology, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, The Netherlands.; Antoni van Leeuwenhoek/Netherlands Cancer Institute, Department of Gynecologic Oncology, Center of Gynecologic Oncology Amsterdam, Amsterdam, The Netherlands., Bleeker MCG; Amsterdam UMC, location Vrije Universiteit Amsterdam, Department of Pathology, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, The Netherlands., van den Burgt Y; Amsterdam UMC, location Vrije Universiteit Amsterdam, Department of Pathology, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, The Netherlands., van den Helder R; Amsterdam UMC, location Vrije Universiteit Amsterdam, Department of Pathology, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, The Netherlands.; Antoni van Leeuwenhoek/Netherlands Cancer Institute, Department of Gynecologic Oncology, Center of Gynecologic Oncology Amsterdam, Amsterdam, The Netherlands., Lok CAR; Antoni van Leeuwenhoek/Netherlands Cancer Institute, Department of Gynecologic Oncology, Center of Gynecologic Oncology Amsterdam, Amsterdam, The Netherlands., Dijk F; Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, The Netherlands.; Amsterdam UMC, location University of Amsterdam, Department of Pathology, Amsterdam, The Netherlands., van der Pol Y; Amsterdam UMC, location Vrije Universiteit Amsterdam, Department of Pathology, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, The Netherlands., Mouliere F; Amsterdam UMC, location Vrije Universiteit Amsterdam, Department of Pathology, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, The Netherlands., Moldovan N; Amsterdam UMC, location Vrije Universiteit Amsterdam, Department of Pathology, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, The Netherlands., van Trommel NE; Antoni van Leeuwenhoek/Netherlands Cancer Institute, Department of Gynecologic Oncology, Center of Gynecologic Oncology Amsterdam, Amsterdam, The Netherlands., Steenbergen RDM; Amsterdam UMC, location Vrije Universiteit Amsterdam, Department of Pathology, Amsterdam, The Netherlands. r.steenbergen@amsterdamumc.nl.; Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, The Netherlands. r.steenbergen@amsterdamumc.nl. |
| المصدر: | Communications medicine [Commun Med (Lond)] 2024 May 16; Vol. 4 (1), pp. 88. Date of Electronic Publication: 2024 May 16. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Nature Portfolio Country of Publication: England NLM ID: 9918250414506676 Publication Model: Electronic Cited Medium: Internet ISSN: 2730-664X (Electronic) Linking ISSN: 2730664X NLM ISO Abbreviation: Commun Med (Lond) Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: [London] : Nature Portfolio, [2021]- |
| مستخلص: | Background: High ovarian cancer mortality rates motivate the development of effective and patient-friendly diagnostics. Here, we explored the potential of molecular testing in patient-friendly samples for ovarian cancer detection. Methods: Home-collected urine, cervicovaginal self-samples, and clinician-taken cervical scrapes were prospectively collected from 54 patients diagnosed with a highly suspicious ovarian mass (benign n = 25, malignant n = 29). All samples were tested for nine methylation markers, using quantitative methylation-specific PCRs that were verified on ovarian tissue samples, and compared to non-paired patient-friendly samples of 110 age-matched healthy controls. Copy number analysis was performed on a subset of urine samples of ovarian cancer patients by shallow whole-genome sequencing. Results: Three methylation markers are significantly elevated in full void urine of ovarian cancer patients as compared to healthy controls (C2CD4D, P = 0.008; CDO1, P = 0.022; MAL, P = 0.008), of which two are also discriminatory in cervical scrapes (C2CD4D, P = 0.001; CDO1, P = 0.004). When comparing benign and malignant ovarian masses, GHSR shows significantly elevated methylation levels in the urine sediment of ovarian cancer patients (P = 0.024). Other methylation markers demonstrate comparably high methylation levels in benign and malignant ovarian masses. Cervicovaginal self-samples show no elevated methylation levels in patients with ovarian masses as compared to healthy controls. Copy number changes are identified in 4 out of 23 urine samples of ovarian cancer patients. Conclusions: Our study reveals increased methylation levels of ovarian cancer-associated genes and copy number aberrations in the urine of ovarian cancer patients. Our findings support continued research into urine biomarkers for ovarian cancer detection and highlight the importance of including benign ovarian masses in future studies to develop a clinically useful test. (© 2024. The Author(s).) |
| References: | J Pers Med. 2022 Jun 29;12(7):. (PMID: 35887570) Nat Commun. 2022 Feb 1;13(1):448. (PMID: 35105887) Cancers (Basel). 2021 Jan 31;13(3):. (PMID: 33572525) Gynecol Oncol. 2022 Jun;165(3):568-576. (PMID: 35370009) Clin Epigenetics. 2020 Nov 3;12(1):165. (PMID: 33143739) Int J Gynecol Cancer. 2022 Dec 5;32(12):1568-1575. (PMID: 36384753) Sci Transl Med. 2018 Mar 21;10(433):. (PMID: 29563323) Lung Cancer. 2022 Aug;170:156-164. (PMID: 35793574) Am J Hum Genet. 2020 Feb 6;106(2):202-214. (PMID: 32004449) Cancer Biol Med. 2017 Feb;14(1):9-32. (PMID: 28443200) EMBO Mol Med. 2021 Aug 9;13(8):e12881. (PMID: 34291583) Sci Rep. 2021 Jan 27;11(1):2363. (PMID: 33504902) Eur J Cancer. 2023 Jan;178:91-113. (PMID: 36427394) Clin Epigenetics. 2023 Feb 14;15(1):24. (PMID: 36788585) Clin Chim Acta. 2021 Nov;522:152-157. (PMID: 34419462) Int J Cancer. 2023 Jul 15;153(2):341-351. (PMID: 36912267) J Clin Oncol. 2022 Nov 20;40(33):3828-3838. (PMID: 36001862) Lancet. 2021 Jun 5;397(10290):2182-2193. (PMID: 33991479) Clin Epigenetics. 2019 Nov 27;11(1):166. (PMID: 31775891) Gynecol Oncol. 2016 Nov;143(2):270-275. (PMID: 27615399) CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338) Clin Cancer Res. 2022 May 13;28(10):2061-2068. (PMID: 35266975) BMJ. 2020 Jul 30;370:m2614. (PMID: 32732303) BMC Cancer. 2012 Nov 23;12:551. (PMID: 23176198) Lancet. 2023 Oct 7;402(10409):1251-1260. (PMID: 37805216) Prev Med Rep. 2022 Feb 28;26:101749. (PMID: 35256928) Cancer Prev Res (Phila). 2020 Sep;13(9):783-794. (PMID: 32581010) Br J Cancer. 2023 Aug;129(2):325-334. (PMID: 37165201) Sci Rep. 2019 Feb 28;9(1):3088. (PMID: 30816167) Nat Protoc. 2008;3(6):1101-8. (PMID: 18546601) J Low Genit Tract Dis. 2019 Jul;23(3):193-199. (PMID: 30933030) Ann Oncol. 2020 Jun;31(6):745-759. (PMID: 33506766) Gynecol Oncol. 2014 Feb;132(2):343-50. (PMID: 24321399) BJOG. 2005 Jul;112(7):857-65. (PMID: 15957984) J Clin Pathol. 2014 Dec;67(12):1067-71. (PMID: 25281766) Papillomavirus Res. 2020 Jun;9:100193. (PMID: 32171935) PLoS Genet. 2022 Jul 6;18(7):e1010262. (PMID: 35793278) Lancet Oncol. 2023 Jul;24(7):733-743. (PMID: 37352875) Int J Cancer. 2024 Feb 15;154(4):679-691. (PMID: 37861205) NPJ Genom Med. 2022 Apr 28;7(1):30. (PMID: 35484288) Clin Cancer Res. 2020 Aug 15;26(16):4339-4348. (PMID: 32430478) Genome Med. 2017 Dec 22;9(1):116. (PMID: 29268796) BMC Cancer. 2014 May 05;14:315. (PMID: 24886194) Genome Med. 2022 Oct 19;14(1):116. (PMID: 36258199) Eur J Cancer. 2018 Sep;100:55-64. (PMID: 29957561) J Gynecol Oncol. 2019 Sep;30(5):e76. (PMID: 31328458) BMJ Open. 2023 Jun 6;13(6):e068940. (PMID: 37280031) J Gynecol Oncol. 2018 Jan;29(1):e17. (PMID: 29185275) |
| فهرسة مساهمة: | Local Abstract: [plain-language-summary] Ovarian cancer is often found late with limited treatment options. Currently, it is difficult to diagnose ovarian cancer correctly and no recommended early detection or screening methods exist. Our aim was to explore the use of DNA-based tests in patient-friendly samples for ovarian cancer detection. Patient-friendly samples are patient materials that can be collected from home without pain or discomfort, such as self-collected vaginal swabs and urine. Using DNA-based tests, we found that urine of women with ovarian cancer contains ovarian cancer-associated signals. Our findings encourage further development of a potential urine test for ovarian cancer detection. This approach could aid early detection and guide women with ovarian masses to appropriate specialist care. |
| تواريخ الأحداث: | Date Created: 20240516 Latest Revision: 20240519 |
| رمز التحديث: | 20240519 |
| مُعرف محوري في PubMed: | PMC11099128 |
| DOI: | 10.1038/s43856-024-00517-8 |
| PMID: | 38755429 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 2730-664X |
|---|---|
| DOI: | 10.1038/s43856-024-00517-8 |